Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: evaluation report and supporting information
Table of contents
01 - Pre-meeting Briefing
02 - Submission from the technology manufacturer – Novartis
03 - NICE request to the manufacturer for clarification on their submission
04 - Company clarification response
05 - Consultee submission - Allergy UK
06 - Consultee submission - British Association of Dermatologists
07 - Consultee submission - British Society for Allergy and Clinical Immunology
08 - Consultee submission - Royal College of Pathologists
09 - Consultee submission - Royal College of Physicians
10 - Consultee submission - Dermatology Clinical Reference Group (CRG) for Specialised Commissioning, NHS England
11 - Clinical expert personal perspective - Dr Clive Grattan
12 - Patient expert personal perspective - Maureen Jenkins
13 - Clinical expert personal perspective - Dr Shuaib Nasser
14 - Patient expert personal perspective - Deborah Shipman
15 - Clinical expert personal perspective - Dr Sinisa Savic
16 - Evidence Review Group report prepared by Southampton Health Technology Assessments Centre
17 - Erratum to Evidence Review Group report
18 - Evidence Review Group response to the company's factual accuracy check
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: evaluation report and supporting information
19 November 2014 (7.12 Mb 22 sec) |
This page was last updated: 13 November 2014